Making sense of TILs : recommendations for morphological assessment of tumour‐infiltrating lymphocytes in gastro‐oesophageal carcinoma

Read full text
Authors: Ylva Weeda, Roberto Salgado, Filip Van Herpe, Daniel Genel Sur, Michael Vieth, Sherene Loi, Ahmad Pahlavan Tafti, Alexandros Hardas, Akira I. Hida, Amarpreet Bhalla, Andrey Khramtsov, Anna Ehinger
+27 more Atsushi Tanaka, Balázs Ács, Caner Ercan, Cornelia M. Focke, Daniel Ehinger, Donghui Huang, Galina F. Khramtsova, Haruto Nishida, Nianyi Li, Nickolas G. Littlefield, Sanna Steen, Selim Sevim, Shin Ichihara, Shinnosuke Morikawa, Stefan Michiels, Thomas G. Papathomas, Toshihiro Haga, Qiangqiang Gu, Weiqi Sheng, Hoel Kervadec, Hugo M. Horlings, Francisco Sánchez-Vega, Yelena Yuriy Janjigian, Myriam Chalabi, Hanneke W.M. van Laarhoven, Liudmila L. Kodach, Sybren Lodewijk Meijer
Cited by: 0
References: 119

Abstract

In the era of immune checkpoint inhibitors for cancers, the need for prognostic biomarkers to identify patients most likely to achieve a durable response has become increasingly more relevant. Tumour-infiltrating lymphocytes (TILs) have gained significant interest, as they can be evaluated using standard haematoxylin and eosin-stained slides, making it a widely accessible and cost-effective biomarker. In addition to their practicality, TILs provide prognostic insights into the interplay between the immune system and tumour cells. While the morphological assessment of TILs has been standardised in breast cancer, comprehensive guidelines for their evaluation in gastro-oesophageal carcinomas (GEC) are still lacking. This narrative review examines the current literature on the composition, clinical implications and therapeutic utility of TILs in GEC. These insights are used to propose a framework with recommendations for standardised evaluation and reporting of TILs in GEC, while also highlighting pitfalls specific to GEC pathology. These recommendations serve as a vital first step towards the widespread use and validation of TILs as a biomarker.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Gastric Cancer Management and Outcomes T-cell and B-cell Immunology

Publication details

Journal / source
Histopathology
Volume
88
Issue
6
Pages
1126–1141
Publication date
5 February 2026
Language
EN